Almenoff June Sherie's Form 4 filing
Tenax Therapeutics, Inc. (TENX) · filed Nov 19, 2025
- Accession no.
- 0001492647-25-000003
- Filed
- Nov 19, 2025
- Trade date
- Nov 17-18, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $15.0K. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001492647-25-000004 (Nov 20, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Almenoff June SherieCIK 0001492647 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | Common Stock | PPurchaseAcquired | +93 | $7.15 | +$664.95 | 93 | Direct | |
| Nov 18, 2025 | Common Stock | PPurchaseAcquired | +1,900 | $7.52F1 | +$14,288 | 1,993 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.